Levi & Korsinsky Investigates Myriad Genetics for Investors
Law firm Levi & Korsinsky has initiated an investigation into Myriad Genetics. The inquiry follows the company's significant reduction of its financial guidance earlier this year.
Law firm Levi & Korsinsky has launched an investigation into Myriad Genetics, a company specializing in genetic testing services. The probe is being conducted on behalf of the company's investors and centers on a substantial lowering of its financial forecasts.
In May 2026, Myriad Genetics' management reaffirmed its full-year revenue projection at $860-$880 million. However, just three months later, in August 2026, the company revised its guidance downward to $770-$790 million. Concurrently, Myriad Genetics suspended its adjusted EBITDA guidance.
These significant adjustments to the company's financial outlook resulted in losses for its shareholders. Levi & Korsinsky aims to determine whether Myriad Genetics' executives provided investors with misleading information regarding the company's financial condition or failed to disclose material facts.
The investigation will seek to ascertain if the company violated securities laws. Further details regarding any potential misconduct or omissions are expected to be released as the investigation progresses.